| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| FY | 178,799 | 185,007 | 199,727 | 205,129 | 206,603 | - |
| 3Q | 120,227 | 129,525 | 137,046 | 148,078 | 144,557 | 156,169 |
| 2Q | 79,050 | 89,735 | 87,240 | 102,343 | 94,349 | 103,536 |
| 1Q | 34,583 | 38,551 | 38,461 | 47,182 | 44,363 | 48,728 |
2024 3Q (9 months) ended December 31, 2023
Overall sales increased 8.0% over the same period of the previous fiscal year. In Japan, the Company concentrated on enhancing sales activities which match each market; the acute care hospital market, the small and mid-sized hospital market, and the clinic market. The Company also focused on its consumables and services business as well as strengthening its marketing and service capabilities, creating customer value which contributed to improving medical safety, patient outcomes, and operating efficiency. As a result of these initiatives, sales in all markets and all product categories increased. Sales of Physiological Measuring Equipment and Treatment Equipment increased favorably. Sales of Patient Monitors and Other Medical Equipment also increased. Internationally, sales showed double-digit growth due to yen depreciation and the impact of a change in the fiscal term of Defibtech, LLC according to the reorganization of subsidiaries in the U.S. Sales of all product categories increased. Sales of Treatment Equipment showed strong growth, because sales of Defibtech AEDs and a mask-type ventilator increased significantly. Sales of Physiological Measuring Equipment also achieved double-digit growth. Sales of Patient Monitors and Other Medical Equipment decreased on a local currency basis and increased on a yen basis.
*Defibtech, LLC changed its fiscal term from end on December 31 to end on March 31, according to the reorganization of U.S. subsidiaries. In the nine months ended December 31, 2023, Nihon Kohden consolidated the 12 months of Defibtech’s operating results from January 1, 2023 to December 31, 2023.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| FY | 15,044 | 15,503 | 27,094 | 30,992 | 21,120 | - |
| 3Q | 6,365 | 8,396 | 15,586 | 23,316 | 11,377 | 10,515 |
| 2Q | 4,260 | 7,009 | 8,758 | 17,414 | 7,217 | 7,491 |
| 1Q | 53 | 542 | 1,831 | 6,423 | 1,817 | 2,205 |
2024 3Q (9 months) ended December 31, 2023
Operating income decreased 7.6% due to an increase in SG&A expenses resulting from the strengthening of human resources and R&D investment, as well as costs from the reform of the profit structure starting from the third quarter of FY2023.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| FY | 15,867 | 14,846 | 28,374 | 34,563 | 24,122 | - |
| 3Q | 7,143 | 8,108 | 14,697 | 24,677 | 13,937 | 13,258 |
| 2Q | 5,270 | 6,334 | 8,215 | 17,990 | 13,019 | 12,546 |
| 1Q | 580 | -26 | 1,581 | 6,743 | 5,481 | 5,794 |
2024 3Q (9 months) ended December 31, 2023
Ordinary income decreased 4.9%.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| FY | 11,191 | 9,854 | 18,243 | 23,435 | 17,110 | - |
| 3Q | 4,986 | 4,832 | 8,882 | 16,911 | 8,860 | 7,926 |
| 2Q | 3,916 | 3,943 | 5,826 | 12,294 | 8,541 | 7,997 |
| 1Q | 538 | -499 | 1,060 | 4,537 | 3,679 | 3,787 |
2024 3Q (9 months) ended December 31, 2023
Income attributable to owners of parent decreased 10.5%.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| FY | 131.43 | 115.72 | 214.21 | 276.51 | 203.28 | - |
| 3Q | 58.56 | 56.75 | 104.30 | 199.36 | 105.25 | 94.20 |
| 2Q | 45.99 | 46.31 | 68.42 | 144.85 | 101.43 | 95.05 |
| 1Q | 6.33 | -5.86 | 12.46 | 53.38 | 43.66 | 45.02 |
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| FY | 169,717 | 167,786 | 193,030 | 210,201 | 216,728 | - |
| 3Q | 153,841 | 154,304 | 170,521 | 191,981 | 206,011 | 215,788 |
| 2Q | 153,525 | 157,556 | 168,512 | 189,754 | 209,292 | 220,990 |
| 1Q | 149,855 | 154,902 | 161,362 | 180,514 | 203,115 | 216,444 |
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| FY | 116,087 | 121,774 | 138,986 | 156,381 | 167,604 | - |
| 3Q | 111,120 | 118,163 | 127,733 | 150,175 | 161,242 | 171,479 |
| 2Q | 112,671 | 117,818 | 126,853 | 147,144 | 162,424 | 174,305 |
| 1Q | 108,017 | 113,988 | 121,577 | 139,525 | 156,453 | 169,587 |
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| FY | 68.4 | 72.6 | 72.0 | 74.4 | 77.3 | - |
| 3Q | 72.2 | 76.6 | 74.9 | 78.2 | 78.3 | 79.5 |
| 2Q | 73.4 | 74.8 | 75.3 | 77.5 | 77.6 | 78.9 |
| 1Q | 72.1 | 73.6 | 75.3 | 77.3 | 77.0 | 78.4 |
Caution
-
These data are prepared based on the financial results reports.
-
The frequency of updates may change in accordance with changes to the format of the financial results reports.
-
Please see the financial results reports and other materials for detailed information regarding the settlement of accounts.
-
The contents of these data will not immediately reflect corrections to the financial results reports when announced.
-
While we pay due caution to the conversion of data for the posting, please note that there is a possibility that errors may occur in the information due to uncontrollable circumstances, such as the unauthorized alteration of contents by a third party or mechanical defects resulting from equipment malfunction.
-
Service provided by Nomura Investor Relations Co., Ltd.
Powered by ShareWith
